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s the Cholesteryl
ster Transfer Protein
roatherogenic or
ntiatherogenic in Humans?*
arina Cuchel, MD, PHD, Daniel J. Rader, MD
hiladelphia, Pennsylvania
he strong inverse association of plasma levels of high-
ensity lipoprotein cholesterol (HDL-C) with coronary
eart disease (CHD) has long tantalized the preventive
ardiovascular medicine community with the prospect of
ew therapies that raise levels of HDL-C and thus reduce
he risk of CHD. The finding that markedly elevated
DL-C levels are caused by genetic deficiency of the
holesteryl ester transfer protein (CETP) and, subsequently,
See page 1948
hat pharmacologic inhibition of CETP substantially raises
evels of HDL-C in humans only served to promote the
nticipation of a major new therapeutic breakthrough in the
revention of CHD. However, this concept suffered a
ubstantial blow with the demise of the CETP inhibitor
orcetrapib in December 2006 due to a 60% increase in
ortality in the actively treated group of a large outcome
rial called ILLUMINATE (Investigation of Lipid Level
anagement to Understand its iMpact IN ATherosclerotic
vents) (1). Further disappointment came from the results
f atherosclerosis imaging trials indicating no significant
ffects on progression of coronary atherosclerosis or carotid
ntimal medial thickness (IMT) despite increases of
DL-C of 50% (2,3) Importantly, however, torcetrapib
aises blood pressure in some individuals through a mech-
nism unrelated to CETP inhibition, and therefore it is
nclear whether the disappointing results with torcetrapib
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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unded by NIH grants from the NHLBI, the National Institute of Diabetes and
igestive and Kidney Diseases, and the National Center for Research Resources.re due to inhibition of CETP or to off-target effects of the
rug (4). The question of whether CETP is pro- or
ntiatherogenic, and therefore whether inhibition of CETP
sing a different inhibitor might be beneficial, is critically
mportant not only to the concept of whether CETP
nhibition is still a viable approach, but also to the broader
ssue of targeting HDL-C therapeutically.
Cholesteryl ester transfer protein mediates the transfer of
holesteryl esters (CE) from HDL to apolipoprotein (apo)
-containing triglyceride-enriched remnant lipoproteins in
xchange for triglycerides. After acquiring HDL-derived
E, apoB-containing lipoproteins can then be cleared by
he low-density lipoprotein (LDL) receptors in the liver.
his pathway has been proposed as the major pathway in
umans by which HDL-derived cholesterol is transported
ack to the liver (5), and studies in mice engineered to express
ETP support this concept (6). Furthermore, triglyceride-
nriched HDL are a good substrate for hepatic lipase, which,
ia its action on HDL, may favor the production of lipid-poor
poA-I (7), a major acceptor of cholesterol efflux. Thus, it is
heoretically possible that reduced levels of CETP activity
ould result in reduced reverse cholesterol transport due
oth to reduced generation of lipid-poor apoA-I as well as
o reduced rate of return of HDL-derived cholesterol to the
iver for excretion. This concept, coupled with the torce-
rapib experience, makes it imperative to discern the true
elationship between CETP and atherogenesis in humans.
This has been a central question ever since the discovery
f CETP deficiency as a cause of elevated HDL-C levels,
nd, surprisingly, it remains unanswered. Studies in the
elatively small number of homozygous CETP-deficient
ubjects in Japan have suggested either increased or de-
reased risk of CHD (8,9) and this issue is still debated.
tudies of heterozygous CETP-deficient subjects in the
onolulu Heart Study have not been definitive either (10).
imilarly, studies investigating the association between
ommon variants in the human CETP gene and cardiovas-
ular disease have yielded contradictory results despite consis-
ent associations with HDL-C levels (11). Thus, genetic
tudies have not answered the question of the relationship of
ETP to atherosclerosis.
Studies that focus on the association between plasma
ETP protein mass levels and CHD outcomes may have
he potential to clarify this issue, but relatively few studies
ave been published and they do not provide a consistent
essage. Higher CETP protein levels were associated with
revalent CHD (12), faster progression of angiographic
AD (13), faster progression of carotid IMT (14), and
reater risk of incident CHD events in a nested case-control
tudy within the EPIC (European Prospective Investigation
nto Cancer and Nutrition)-Norfolk study (15). However,
o differences in CETP protein levels were observed in a
mall study of patients undergoing coronary angiography
16) and in a nested case-control study within the
REVEND (Prevention of Renal and Vascular End-Stage
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November 13, 2007:1956–8 Editorial Commentisease) study (17). Finally, lower CETP protein levels
ere found to be associated with increased CHD events in
prospective study of patients treated with a statin (18). It
s possible that these discrepant results are due to confound-
ng factors that may alter the relationship between CETP
rotein levels and CHD outcomes. For example, the posi-
ive association between CETP protein levels and CHD
vents in the EPIC-Norfolk study was restricted to those
ubjects with higher triglyceride levels (15). In contrast, in
he PREVEND study, lower CETP protein levels were
redictive of increased CHD events only in the subjects
ith lower triglycerides (19).
The role of CETP in influencing atherogenesis is in turn
nfluenced by the metabolic milieu in which CETP oper-
tes. Low-density lipoprotein cholesterol and triglyceride
evels, lifestyle habits such as smoking and alcohol use, and
rugs such as statins have all been shown to affect plasma
ETP activity. Measures of CETP activity may therefore
e more informative than those of CETP protein mass, but
ssays are not standardized and are cumbersome to perform
n the large numbers required in observational studies. In a
mall study of subjects undergoing coronary angiography,
igher CETP activity was found in subjects with angio-
raphic coronary disease compared with controls (20). More
ecently, a significant positive association between CETP
ctivity and carotid IMT was found in both diabetic and
ondiabetic subjects (21). Given the relative paucity of data,
he article by Zeller et al. (22) in this issue of the Journal is
welcome addition to the literature. This paper reports the
esults obtained in a study evaluating plasma CETP activity
nd protein levels in sequential subjects admitted with first
yocardial infarction. Subjects in the highest tertile of
ETP activity had statistically higher CETP protein levels,
otal cholesterol, LDL-C, non–HDL-C, and triglycerides,
ad lower HDL-C, had a higher percentage of smokers,
nd were also significantly younger. A multiple linear
egression analysis indicated that the younger age of the
ubjects with higher CETP activity was independent of
ther potentially confounding risk factors, suggesting that
igher CETP activity is an independent risk factor for early
yocardial infarction. The focus on CETP activity in this
tudy is commendable. However, measuring CETP activity
as some limitations that need to be considered. Zeller et al.
22) measured CETP activity by using a method that is very
ependent on the concentration of endogenous apoB-
ontaining lipoproteins as acceptor particles, which them-
elves are highly atherogenic. In this context, elevated
ETP activity could be a surrogate for elevated levels of
emnant lipoproteins; indeed, upon multivariate analysis,
on–HDL-C levels were an independent predictor of
ETP activity. Thus it remains uncertain whether the
levated CETP activity is causal or simply a sophisticated
iomarker for a more atherogenic lipoprotein profile. Nev-
rtheless, these results generally support a proatherosclerotic
ole of CETP.In light of the importance of this question, further studies
hat carefully assess the relationship of plasma CETP
rotein mass and activity to CHD in the context of a
arefully defined metabolic milieu and controlling for de-
ailed measures of atherogenic lipoproteins are still needed
nd may be important in helping to determine the future of
ETP inhibition as a therapeutic strategy.
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